- Home
- GNLX vs ANVS Comparison
GNLX vs ANVS Comparison
Compare GNLX & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | ANVS |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 111.3M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNLX | ANVS |
|---|---|---|
| Price | $2.58 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $19.75 | $13.50 |
| AVG Volume (30 Days) | 129.5K | ★ 322.7K |
| Earning Date | 01-01-0001 | 06-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.10 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $1.11 |
| 52 Week High | $8.54 | $5.50 |
Technical Indicators
Market Signals| Indicator | GNLX | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 44.59 |
| Support Level | $2.54 | $2.29 |
| Resistance Level | $2.86 | $2.63 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 12.75 | 10.49 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.